RxDoctor Payments Data

Juanita Gaines, MD

Internal Medicine · Cincinnati, OHNPI 1801826763

Payments from drug & device makers

$5,074in general payments, 2019–2025

Across 313 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$697
  • Johnson & Johnson$550
  • AstraZeneca$459
  • GSK$441
  • Lilly USA, LLC$393
  • AbbVie$359
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$5,064100%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,074 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$35,375
Medicare patients
87
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin107$114,420
FarxigaDapagliflozin Propanediol74$68,405
OzempicSemaglutide49$64,891
MounjaroTirzepatide59$63,736
EliquisApixaban74$55,841
TrulicityDulaglutide47$51,933
CreonLipase/Protease/Amylase41$50,749
XareltoRivaroxaban33$39,339
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$34,817
VraylarCariprazine Hcl18$26,433
SymbicortBudesonide/Formoterol Fumarate50$19,795
KerendiaFinerenone17$18,633
RybelsusSemaglutide11$17,631
JanuviaSitagliptin Phosphate18$16,702
NexletolBempedoic Acid16$12,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$459$123,018160 claims
Lilly USA, LLCMounjaro, Trulicity$393$115,669106 claims
Boehringer IngelheimJardiance$189$114,420107 claims
Novo NordiskOzempic, Rybelsus$697$82,52260 claims
AbbVieCreon, Vraylar, Viibryd$359$81,70771 claims
PfizerEliquis$272$55,84174 claims
Johnson & JohnsonXarelto$550$39,33933 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$73$21,62030 claims
BayerKerendia$123$18,63317 claims
MerckJanuvia$108$16,70218 claims
GSKAnoro Ellipta, Breo Ellipta$441$9,65023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →